Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
Wall Street kicked off the week on a high note, with the S&P 500 and Nasdaq 100 reaching new highs in anticipation of the January inflation report scheduled for this Tuesday.
Parikh maintains Outperform rating on WMT, raises price target to $185. Bull case still in early to middle innings, potential for continued outperformance. Optimistic about PhonePe and Flipkart IPO unlocking more value. WMT remains top pick, shares up 8% YTD.
Hershey faces stock downgrade as Morgan Stanley analyst cites concerns over mixed Q4 earnings and bleak midterm outlook amidst cocoa inflation and weakened consumer demand. Analyst Pamela Kaufman predicts input cost inflation and gross margin contraction, leading to lowered EPS estimates for 2025, despite Hershey's proactive measures and investment plans in innovation.